Perceptive Advisors LLC Buys Shares of 14,400 bluebird bio Inc (BLUE)
Perceptive Advisors LLC bought a new stake in shares of bluebird bio Inc (NASDAQ:BLUE) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 14,400 shares of the biotechnology company’s stock, valued at approximately $2,565,000.
Several other hedge funds have also added to or reduced their stakes in BLUE. Two Sigma Advisers LP grew its holdings in shares of bluebird bio by 3,004.0% during the 4th quarter. Two Sigma Advisers LP now owns 462,500 shares of the biotechnology company’s stock valued at $82,371,000 after purchasing an additional 447,600 shares during the last quarter. Eagle Asset Management Inc. bought a new position in shares of bluebird bio during the 3rd quarter valued at $29,539,000. BlackRock Inc. grew its holdings in shares of bluebird bio by 6.4% during the 4th quarter. BlackRock Inc. now owns 3,831,371 shares of the biotechnology company’s stock valued at $682,366,000 after purchasing an additional 231,697 shares during the last quarter. American Century Companies Inc. bought a new position in shares of bluebird bio during the 3rd quarter valued at $31,170,000. Finally, Franklin Resources Inc. grew its holdings in shares of bluebird bio by 41.3% during the 4th quarter. Franklin Resources Inc. now owns 686,900 shares of the biotechnology company’s stock valued at $122,337,000 after purchasing an additional 200,900 shares during the last quarter.
Several equities analysts recently commented on the stock. BTIG Research increased their target price on shares of bluebird bio to $250.00 and gave the company a “buy” rating in a report on Thursday, March 8th. Leerink Swann lowered shares of bluebird bio from an “outperform” rating to a “market perform” rating and raised their price target for the stock from $162.00 to $194.00 in a report on Thursday, January 25th. Cantor Fitzgerald reissued a “sell” rating and issued a $113.00 price target (down previously from $122.00) on shares of bluebird bio in a report on Wednesday, February 21st. BMO Capital Markets set a $222.00 price target on shares of bluebird bio and gave the stock a “buy” rating in a report on Thursday, February 22nd. Finally, Sanford C. Bernstein reissued a “hold” rating and issued a $211.00 price target (up previously from $153.00) on shares of bluebird bio in a report on Thursday, February 22nd. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $187.60.
bluebird bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, February 21st. The biotechnology company reported ($2.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.84). The company had revenue of $4.17 million for the quarter, compared to the consensus estimate of $7.11 million. bluebird bio had a negative net margin of 947.42% and a negative return on equity of 28.09%. The company’s revenue for the quarter was up 169.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.88) EPS. equities analysts expect that bluebird bio Inc will post -8.25 earnings per share for the current year.
In other news, insider Nick Leschly sold 117,500 shares of bluebird bio stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $184.08, for a total transaction of $21,629,400.00. Following the sale, the insider now owns 293,232 shares of the company’s stock, valued at approximately $53,978,146.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jason Cole sold 25,000 shares of bluebird bio stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $195.91, for a total transaction of $4,897,750.00. Following the sale, the insider now directly owns 44,798 shares in the company, valued at approximately $8,776,376.18. The disclosure for this sale can be found here. Insiders have sold a total of 182,098 shares of company stock worth $33,999,709 in the last ninety days. Insiders own 3.90% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Perceptive Advisors LLC Buys Shares of 14,400 bluebird bio Inc (BLUE)” was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/perceptive-advisors-llc-buys-shares-of-14400-bluebird-bio-inc-blue/1927732.html.
bluebird bio Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.